Pomerantz Law Firm Alerts Cassava Sciences Investors About Class Action Filing and Key Dates

Legal Update: Class Action Lawsuit Against Cassava Sciences

On January 8, 2025, Pomerantz LLP announced the filing of a class action lawsuit against Cassava Sciences, Inc. (NASDAQ: SAVA), a firm involved in the research and development of treatments for Alzheimer’s disease. This class action targets investors who experienced losses due to potential securities fraud or other unlawful business practices allegedly engaged in by Cassava and its officers.

With a deadline set for February 10, 2025, shareholders who have incurred losses and purchased Cassava securities during the specified class period are urged to join the lawsuit. If you're affected, you can contact Danielle Peyton at Pomerantz LLP via email or telephone for guidance and further details on joining the class action. Investors are recommended to provide their mailing address, phone number, and the number of shares acquired to facilitate the process.

The lawsuit comes after negative news on November 25, 2024, when Cassava reported disappointing results from its Phase 3 clinical trial for simufilam, a drug intended for Alzheimer’s treatment. The study revealed that simufilam failed to meet crucial pre-specified endpoints, leading the company to pull out from an additional trial. Following this announcement, the stock price plummeted by nearly 84%, resulting in severe financial distress for many investors.

Pomerantz LLP, a well-respected firm with expertise in corporate and securities litigation, has a long history of advocating for the rights of shareholders. Their commitment to holding corporations accountable has resulted in recoveries of billions in damages. This most recent class action adds to their storied reputation, as they continue to navigate the complexities of securities fraud and corporate misconduct.

As investors review their options, it’s vital to stay informed about the potential implications of this lawsuit and actively participate if eligible. The outcomes could hinge on the collective effort of affected shareholders banding together. In light of the significant price drop and the company's subsequent actions, those with stakes in Cassava are justified to seek legal recourse.

Stay vigilant and act swiftly if you’ve been impacted by this situation. More information regarding the specifics of the lawsuit and how to get involved can be found on the Pomerantz Law Firm's website.

For further inquiries about the class action lawsuit or details about your potential claim against Cassava Sciences, do not hesitate to get in touch with Pomerantz LLP. Remember that timely engagement is crucial to securing your position in this legal battle.